Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
about
Transglutaminase 2-mediated serotonylation in pulmonary hypertensionA Sex-Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of Pulmonary HypertensionIncreased contractile response to 5-hydroxytryptamine1-receptor stimulation in pulmonary arteries from chronic hypoxic rats: role of pharmacological synergyIncreased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.Serotonin induces pulmonary artery smooth muscle cell migration.Activation of the unfolded protein response is associated with pulmonary hypertension.Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms.Hypothesis: neuroendocrine mechanisms (hypothalamus-growth hormone-STAT5 axis) contribute to sex bias in pulmonary hypertension.Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteriesPulmonary hypertension: therapeutic targets within the serotonin system.Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.Serotonin and serotonin transport in the regulation of lactation.5-HT moduline: an endogenous inhibitor of 5-HT(1B/1D)-mediated contraction in pulmonary arteries.Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.Mechanisms involved in the regulation of bovine pulmonary vascular tone by the 5-HT1B receptor.Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha).In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension.Halothane differentially decreases 5-hydroxytryptamine-induced contractions in normal and chronic hypoxic rat pulmonary arteries.Amplification of sumatriptan-induced contraction in rabbit saphenous vein but not in basilar artery.The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux.Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors.Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series).
P2860
Q27027862-4A328629-B213-4549-AC8C-EDB0B799D248Q28117980-B1C002D8-AE7B-4DB0-BD8B-0C1B13651C49Q28361077-AFE8D577-46FA-4C1D-8D6D-95C165A9581CQ28567348-5210670F-114C-448C-941F-52F1B4B6761BQ34035781-3C1B8979-42BE-4903-9694-655C82DB9CC6Q35695503-67016D1E-83FD-4783-AF8A-D4AED024ED41Q36108064-C09EB2C8-0C1D-44B0-90E4-2AA861E14D44Q36228769-D8A53AB2-CFDB-4B50-8E15-69BF68B1503EQ36568290-5EBCB293-66CF-4ACB-B687-68ABD6B27994Q37077630-8135C0E7-A1BB-4040-BE82-7E4627E8CA38Q37184405-8183D6B5-52CD-41F2-ADDF-35ED933FE6AFQ37316467-9F2C5267-93DF-4DB9-88CB-29B8719054BEQ37359377-8D19DD11-66B1-49D7-8323-F7F90426F87BQ38153630-EA38DA9A-0954-4DBF-9C5B-14DB5928434DQ41972338-62418200-60D1-4B3E-855D-36F8D0952948Q42701879-31202C49-A59E-4331-BD85-78D307F83144Q42914141-3449B4C4-8137-4908-BF13-D103E18D3864Q43264408-CEAB26F7-F099-48C7-A323-BFB38CA5A186Q43264509-69DB6F5E-24E5-41E1-83DC-321E26996178Q43279828-7B102466-C8F8-4D04-9ECE-E22B8577E2FCQ43817607-2510567A-2430-42D4-AFCB-BB9A8E566769Q44210987-F034EA80-2046-4C95-ADC2-DA2FC95C0DE4Q44693038-D85AB366-3249-4F56-BDD5-66AF4B5A1CD1Q44969041-6E926CF2-85A3-4869-A1C4-856E069D97CFQ54476060-E566AB7B-0969-4282-A64E-FF56BC316AF5Q55394065-B60D08A9-ED90-4D7A-B180-509A42CC00B4
P2860
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
@ast
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
@en
type
label
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
@ast
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
@en
prefLabel
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
@ast
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
@en
P1476
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
@en
P2093
MacLean MR
P304
P356
10.1016/S0165-6147(99)01389-9
P577
1999-12-01T00:00:00Z